Overview and historical development of dexrazoxane.
Dexrazoxane prevents the dose-limiting cardiotoxicity of the anthracyclines without reducing their antitumor efficacy and without new adverse side effects. Dexrazoxane reduces the severity of gastrointestinal symptoms of the anthracycline containing combination doxorubicin, 5-fluorouracil, cyclophosphamide and most surprisingly and importantly, dexrazoxane increases the median survival time of advanced breast cancer responders to the doxorubicin, 5-fluorouracil, cyclophosphamide regimen. The median survival time is doubled as compared to controls to nearly 3 years.
Hellmann
K
K
Windleshaw House, Withyham, East Sussex, England.
D000328:Adult; D018943:Anthracyclines / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D006331:Heart Diseases / Q000139:chemically induced* / Q000517:prevention & control; D006801:Humans; D011929:Razoxane / Q000627:therapeutic use*
D018943:Anthracyclines; D000970:Antineoplastic Agents; D002317:Cardiovascular Agents; D011929:Razoxane